Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 4 de 4
Filtrar
Más filtros










Base de datos
Intervalo de año de publicación
1.
Alzheimers Dement ; 17(12): 1976-1987, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-33984181

RESUMEN

INTRODUCTION: Biomarkers that reflect pathologic processes affecting neuronal function during preclinical and early stages of Alzheimer's disease (AD) are needed to aid drug development. METHODS: A targeted, stable isotope, quantitative mass spectrometry-based investigation of longitudinal changes in concentrations of previously identified candidate biomarkers was performed in cerebrospinal fluid (CSF) of Alzheimer's Disease Neuroimaging Initiative participants who were classified as cognitively normal (CN; n = 76) or with mild cognitive impairment (MCI; n = 111) at baseline. RESULTS: Of the candidate biomarkers, the CSF concentration of neuronal pentraxin 2 (NPTX2), a protein involved in synaptic function, exhibited rates of change that were significantly different between three comparison groups (i.e., CN vs. MCI participants; AD pathology positive vs. negative defined by phosphorylated tau181/amyloid beta1-42 ratio; and clinical progressors vs. non-progressors). The rate of change of NPTX2 also significantly correlated with declining cognition. DISCUSSION: CSF NPTX2 concentration is a strong prognostic biomarker candidate of accelerated cognitive decline with potential use as a therapeutic target.


Asunto(s)
Enfermedad de Alzheimer , Biomarcadores/líquido cefalorraquídeo , Proteína C-Reactiva/líquido cefalorraquídeo , Disfunción Cognitiva , Proteínas del Tejido Nervioso/líquido cefalorraquídeo , Proteómica , Anciano , Enfermedad de Alzheimer/líquido cefalorraquídeo , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/líquido cefalorraquídeo , Disfunción Cognitiva/líquido cefalorraquídeo , Disfunción Cognitiva/patología , Humanos , Estudios Longitudinales , Espectrometría de Masas , Fosforilación , Proteínas tau/líquido cefalorraquídeo
2.
Neurobiol Dis ; 22(2): 404-20, 2006 May.
Artículo en Inglés | MEDLINE | ID: mdl-16439141

RESUMEN

Sporadic Parkinson's disease (PD) is most likely caused by a combination of environmental exposures and genetic susceptibilities, although there are rare monogenic forms of the disease. Mitochondrial impairment at complex I, oxidative stress, alpha-synuclein aggregation, and dysfunctional protein degradation, have been implicated in PD pathogenesis, but how they are related to each other is unclear. To further evaluated PD pathogenesis here, we used in vivo and in vitro models of chronic low-grade complex I inhibition with the pesticide rotenone. Chronic rotenone exposure in vivo caused oxidative modification of DJ-1, accumulation of alpha-synuclein, and proteasomal impairment. Interestingly, the effects become more regionally restricted such that systemic complex I inhibition eventually results in highly selective degeneration of the nigrostriatal pathway. DJ-1 modifications, alpha-synuclein accumulation, and proteasomal dysfunction were also seen in vitro and these effects could be prevented with alpha-tocopherol. Thus, chronic exposure to a pesticide and mitochondrial toxin brings into play three systems, DJ-1, alpha-synuclein, and the ubiquitin-proteasome system, and implies that mitochondrial dysfunction and oxidative stress link environmental and genetic forms of the disease.


Asunto(s)
Degeneración Nerviosa/inducido químicamente , Proteínas Oncogénicas/efectos de los fármacos , Trastornos Parkinsonianos/inducido químicamente , Complejo de la Endopetidasa Proteasomal/efectos de los fármacos , Rotenona/toxicidad , Ubiquitina/efectos de los fármacos , alfa-Sinucleína/efectos de los fármacos , Animales , Línea Celular Tumoral , Modelos Animales de Enfermedad , Complejo I de Transporte de Electrón/efectos de los fármacos , Complejo I de Transporte de Electrón/fisiología , Metabolismo Energético/efectos de los fármacos , Metabolismo Energético/fisiología , Humanos , Insecticidas/toxicidad , Masculino , Mitocondrias/efectos de los fármacos , Mitocondrias/metabolismo , Degeneración Nerviosa/metabolismo , Degeneración Nerviosa/fisiopatología , Neuronas/efectos de los fármacos , Neuronas/metabolismo , Proteínas Oncogénicas/metabolismo , Estrés Oxidativo/efectos de los fármacos , Estrés Oxidativo/fisiología , Trastornos Parkinsonianos/metabolismo , Trastornos Parkinsonianos/fisiopatología , Peroxirredoxinas , Complejo de la Endopetidasa Proteasomal/metabolismo , Proteína Desglicasa DJ-1 , Ratas , Ratas Endogámicas Lew , Transducción de Señal/efectos de los fármacos , Transducción de Señal/fisiología , Sustancia Negra/efectos de los fármacos , Sustancia Negra/metabolismo , Sustancia Negra/fisiopatología , Ubiquitina/metabolismo , alfa-Sinucleína/metabolismo
3.
Brain Res Mol Brain Res ; 134(1): 76-83, 2005 Mar 24.
Artículo en Inglés | MEDLINE | ID: mdl-15790532

RESUMEN

Mutations in the DJ-1 gene are associated with recessive, early onset Parkinson's disease (PD). We reported previously that one of the point mutations, L166P, destabilizes the protein and thus produces an effective knockout of the gene. Here, we have expanded this analysis to include a series of mutations and polymorphisms identified throughout the gene. The M26I point mutation was also unstable, although the effect was not as dramatic as with L166P. Protein levels were rescued in part, but not completely, by proteasome inhibition. Other variants, such as R98Q, were generally stable. We noted that M26I and L166P are both in helical regions near the dimer interface. However, M26I retains the ability to dimerize. We also examined the subcellular localization of DJ-1 and found that most mutations were similar to the wild-type (wt) protein in that a few cells showed mitochondrial staining. However, in all cases, the proportion of cells with mitochondrial DJ-1 staining was increased in oxidative conditions, suggesting that oxidation promotes the mitochondrial localization of DJ-1.


Asunto(s)
Acetilcisteína/análogos & derivados , Proteínas Oncogénicas/genética , Mutación Puntual , Polimorfismo Genético , Acetilcisteína/farmacología , Cloruro de Amonio/farmacología , Análisis de Varianza , Animales , Western Blotting/métodos , Línea Celular Tumoral , Cicloheximida/farmacología , Inhibidores de Cisteína Proteinasa/farmacología , Dimerización , Técnica del Anticuerpo Fluorescente/métodos , Regulación de la Expresión Génica/efectos de los fármacos , Regulación de la Expresión Génica/fisiología , Proteínas Fluorescentes Verdes/metabolismo , Humanos , Inmunoprecipitación/métodos , Péptidos y Proteínas de Señalización Intracelular , Ratones , Modelos Moleculares , Neuroblastoma , Proteínas Oncogénicas/química , Proteína Desglicasa DJ-1 , Inhibidores de la Síntesis de la Proteína/farmacología , ARN Mensajero/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa/métodos , Fracciones Subcelulares/metabolismo , Factores de Tiempo , Transfección/métodos
4.
Proc Natl Acad Sci U S A ; 101(24): 9103-8, 2004 Jun 15.
Artículo en Inglés | MEDLINE | ID: mdl-15181200

RESUMEN

Loss-of-function DJ-1 mutations can cause early-onset Parkinson's disease. The function of DJ-1 is unknown, but an acidic isoform accumulates after oxidative stress, leading to the suggestion that DJ-1 is protective under these conditions. We addressed whether this represents a posttranslational modification at cysteine residues by systematically mutating cysteine residues in human DJ-1. WT or C53A DJ-1 was readily oxidized in cultured cells, generating a pI 5.8 isoform, but an artificial C106A mutant was not. We observed a cysteine-sulfinic acid at C106 in crystalline DJ-1 but no modification of C53 or C46. Oxidation of DJ-1 was promoted by the crystallization procedure. In addition, oxidation-induced mitochondrial relocalization of DJ-1 and protection against cell death were abrogated in C106A but not C53A or C46A. We suggest that DJ-1 protects against neuronal death, and that this is signaled by acidification of the key cysteine residue, C106.


Asunto(s)
Cisteína/análogos & derivados , Cisteína/metabolismo , Mitocondrias/metabolismo , Fármacos Neuroprotectores/metabolismo , Proteínas Oncogénicas/metabolismo , 1-Metil-4-fenilpiridinio/toxicidad , Sustitución de Aminoácidos , Línea Celular Tumoral , Cisteína/química , Cisteína/genética , Humanos , Membranas Intracelulares/metabolismo , Péptidos y Proteínas de Señalización Intracelular , Modelos Moleculares , Neurotransmisores , Proteínas Oncogénicas/química , Proteínas Oncogénicas/genética , Oxidación-Reducción , Estrés Oxidativo , Proteína Desglicasa DJ-1 , Isoformas de Proteínas , Proteínas Recombinantes/química , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Electricidad Estática , Transfección
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA
...